Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Nov 21;12(43):7047-50.
doi: 10.3748/wjg.v12.i43.7047.

Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity

Su-Ping Sun  1 , Ya-Zhou Liu, Tao Ye, Wen Zhang, Wen-Bin Shen, Jing-Lei Shi, Hai-Ting Xu, Wei-Dong Wang
Affiliations
Randomized Controlled Trial

Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity

Su-Ping Sun et al. World J Gastroenterol. .

Abstract

Aim: Tumor response and normal tissue toxicity of seven-day-per-week continuous accelerated irradiation (CAIR) for patients with esophageal carcinoma were evaluated and compared to conventional irradiation (CR).

Methods: Sixty patients with squamous cell carcinoma of the esophagus were randomized into two groups: the CAIR group (30 patients) and the CR group (30 patients). Patients in the CAIR group received radiotherapy (RT) with 2 Gy/fraction per day at 7 d/wk with a total dose of 50-70 Gy (average dose 64.2 Gy). The overall time of irradiation was 3.6-5.0 wk (average 4.6 wk). RT in the CR group was 2 Gy/fraction per day at 5 d/wk with a total dose of 40-70 Gy (average dose 61.7 Gy). The overall time of irradiation was 4.0-7.0 wk (average 6.4 wk).

Results: The data showed that the immediate tumor response to RT was better in the CAIR group than in the CR group. Efficiency rates (CR plus PR) were 82.8% (24/29) and 58.6% (17/29), respectively (P = 0.047). In both groups the incidences of esophagitis and tracheitis were insignificant (P = 0.376, 0.959), and no patient received toxicity that could not be tolerated.

Conclusion: CAIR shortens overall treatment time and is well tolerated by patients. It may be superior to CR in enhancing the local response of tumor, but its remote effect for esophageal carcinoma awaits further follow-up.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hishikawa Y, Kurisu K, Taniguchi M, Kamikonya N, Miura T. High-dose-rate intraluminal brachytherapy for esophageal cancer: 10 years experience in Hyogo College of Medicine. Radiother Oncol. 1991;21:107–114. - PubMed
    1. Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K. Low-dose rate telecobalt therapy as a boost against esophageal carcinomas. Cancer. 1992;69:1099–1103. - PubMed
    1. Wang Y, Shi XH, He SQ, Yao WQ, Wang Y, Guo XM, Wu GD, Zhu LX, Liu TF. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:131–136. - PubMed
    1. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457–467. - PubMed
    1. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146. - PubMed

Publication types